Evolent Health, Inc. (EVH)
| Market Cap | 550.60M -39.0% |
| Revenue (ttm) | 2.10B -4.5% |
| Net Income | -511.06M |
| EPS | -4.54 |
| Shares Out | 113.06M |
| PE Ratio | n/a |
| Forward PE | 13.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 970,896 |
| Open | 4.750 |
| Previous Close | 4.730 |
| Day's Range | 4.750 - 5.120 |
| 52-Week Range | 2.095 - 8.300 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 5.75 (+18.07%) |
| Earnings Date | Nov 5, 2026 |
About EVH
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, an... [Read more]
Financial Performance
In 2025, Evolent Health's revenue was $1.88 billion, a decrease of -26.56% compared to the previous year's $2.55 billion. Losses were -$579.40 million, 520.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for EVH stock is "Buy." The 12-month stock price target is $5.75, which is an increase of 18.07% from the latest price.
News
Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its...
TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
TransPerfect expands its Evolent partnership to provide enterprise-wide telephonic interpretation and strengthen language access for health plan members.
Evolent Health price target raised to $6 from $5 at JPMorgan
JPMorgan analyst John Stansel raised the firm’s price target on Evolent Health (EVH) to $6 from $5 and keeps an Overweight rating on the shares. The firm updated the company’s…
Evolent Health price target raised to $6 from $5 at TD Cowen
TD Cowen raised the firm’s price target on Evolent Health (EVH) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model following Q2…
Citi upgrades Evolent Health to Buy after 30% selloff
Citi upgraded Evolent Health (EVH) to Buy from Neutral with a price target of $6, down from $6.75. The firm updated its ratings and targets in the health and technology…
Evolent Health upgraded to Buy from Neutral at Citi
Citi upgraded Evolent Health (EVH) to Buy from Neutral with a $6 price target
Evolent Health price target lowered to $6 from $7 at Canaccord
Canaccord lowered the firm’s price target on Evolent Health (EVH) to $6 from $7 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Evolent Health Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue and adjusted EBITDA exceed expectations, driven by Performance Suite growth and successful launches with Aetna and Highmark. Full-year guidance was raised, and 2027 is expected to deliver over 25% revenue growth despite Medicaid and exchange headwinds.
Evolent Health Earnings release: Q2 2026
Evolent Health released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Evolent Health Slides: Q2 2026
Evolent Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Evolent Health Quarterly report: Q2 2026
Evolent Health has published its Q2 2026 quarterly earnings report on August 6, 2026.
Evolent Health reports Q2 adjusted EPS 2c, consensus (2c)
Reports Q2 revenue $652.52M, consensus $599.79M. CEO Seth Blackley stated, “We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate…
Evolent Health raises 2026 revenue view to $2.6B-$2.7B from $2.4B-$2.6B
2026 revenue consensus $2.5B. Tightens adjusted EBITDA guidance to $120M-$135M. Expects to deploy $25M-$30M in cash for capitalized software development during 2026.
Evolent Announces Second Quarter 2026 Results
WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through ...
Evolent Health price target lowered to $5 from $8 at TD Cowen
TD Cowen analyst Charles Rhyee lowered the firm’s price target on Evolent Health (EVH) to $5 from $8 and keeps a Buy rating on the shares ahead of the Q2…
Citi downgrades Evolent Health to Neutral on valuation after rally
Citi downgraded Evolent Health (EVH) to Neutral from Buy with a price target of $6.75, up from $5.50. The firm sees a less favorable risk/reward following the stock’s recent rally.
Evolent Health downgraded to Sell from Buy at Citi
Citi analyst Daniel Grosslight downgraded Evolent Health (EVH) to Sell from Buy with a $6.75 price target
Evolent Health price target raised to $7 from $6 at Canaccord
Canaccord raised the firm’s price target on Evolent Health (EVH) to $7 from $6 and keeps a Buy rating on the shares. The firm updated its model heading into the…
Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI.
The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.
Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026
WASHINGTON, July 8, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its...
Evolent Health downgraded to Hold from Buy at Truist
Truist downgraded Evolent Health (EVH) to Hold from Buy with an unchanged price target of $7. The company’s 2027 consensus EBITDA estimates do not fully reflect the headwind from Medicaid…
Evolent Health price target raised to $5.50 from $4 at Citi
Citi raised the firm’s price target on Evolent Health (EVH) to $5.50 from $4 and keeps a Buy rating on the shares.
Evolent Health price target raised to $6 from $5 at Canaccord
Canaccord raised the firm’s price target on Evolent Health (EVH) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model following mixed Q1…
Evolent Health reports Q1 adjusted EPS (2c), consensus (5c)
Reports Q1 revenue $496.25M, consensus $534.04M. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “I am happy with the strong start to the year. We are on track…
Evolent Health Earnings Call Transcript: Q1 2026
Q1 2026 results showed 9% sequential revenue growth and improved MER, driven by new launches and strong demand for oncology solutions. Guidance for 2026 was reiterated, with continued investment in AI and automation and two major new contracts expected to boost future revenue.